A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT ID: NCT04546009

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

992 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-09

Study Completion Date

2028-03-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Giredestrant + Letrozole-matched Placebo + Palbociclib

Group Type EXPERIMENTAL

Giredestrant

Intervention Type DRUG

Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Letrozole-matched Placebo

Intervention Type DRUG

Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Palbociclib

Intervention Type DRUG

Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

LHRH Agonist

Intervention Type DRUG

Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Letrozole + Giredestrant-matched Placebo + Palbociclib

Group Type ACTIVE_COMPARATOR

Giredestrant-matched Placebo

Intervention Type DRUG

Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Letrozole

Intervention Type DRUG

Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Palbociclib

Intervention Type DRUG

Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

LHRH Agonist

Intervention Type DRUG

Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Giredestrant

Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention Type DRUG

Giredestrant-matched Placebo

Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention Type DRUG

Letrozole

Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention Type DRUG

Letrozole-matched Placebo

Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention Type DRUG

Palbociclib

Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

Intervention Type DRUG

LHRH Agonist

Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GDC-9545 RO7197597 RG6171

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For women who are premenopausal or perimenopausal and for men: treatment with approved LHRH agonist therapy for the duration of study treatment
* Locally advanced (recurrent or progressed) or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
* Documented ER-positive tumor and HER2-negative tumor, assessed locally
* Patients who have bilateral breast cancers which are both ER-positive and HER2-negative can be included in the study because the metastases are suitably targeted by the study treatments. If patients have bilateral tumors which are of different biomarker status, then proof of the ER and HER2 status of the metastases is required for study entry
* No history of systemic anti-cancer therapy for locally advanced (recurrent or progressed) or metastatic disease
* Disease recurrence from early-stage breast cancer after standard adjuvant endocrine therapy meeting the protocol-defined criteria of having received at least 24 months of treatment without disease progression during treatment and a disease-free interval since the completion of treatment that was greater than 12 months
* Measurable disease as defined per RECIST v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed
* Eastern Cooperative Oncology Group Performance Status 0-1
* Adequate organ function

Exclusion Criteria

* Disease recurrence during or within 12 months of completing prior neoadjuvant or adjuvant treatment with any CDK4/6 inhibitor
* Prior treatment with a selective estrogen receptor degrader (SERD)
* Treatment with any investigational therapy within 28 days prior to study treatment
* Treatment with strong CYP3A inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to randomization
* Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
* Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease
* Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
* Pregnant or breastfeeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orange Coast Memorial Medical Center

Fountain Valley, California, United States

Site Status

Long Beach Memorial Medical Center

Long Beach, California, United States

Site Status

Kaiser Permanente - San Leandro Medical Center

San Leandro, California, United States

Site Status

Stanford Univ Medical Center

Stanford, California, United States

Site Status

Kaiser Permanente - Walnut Creek

Walnut Creek, California, United States

Site Status

University of Colorado

Aurora, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Denver, Colorado, United States

Site Status

Florida Cancer Specialists - Fort Myers (Broadway)

Fort Myers, Florida, United States

Site Status

Memorial Regional Cancer Ctr

Hollywood, Florida, United States

Site Status

University of Miami

Miami, Florida, United States

Site Status

SCRI Florida Cancer Specialists North

St. Petersburg, Florida, United States

Site Status

SCRI Florida Cancer Specialists PAN

Tallahassee, Florida, United States

Site Status

Kaiser Permanente - Moanalua Medical Center

Honolulu, Hawaii, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Maryland Oncology Hematology

Silver Spring, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

HCA Midwest Division

Kansas City, Missouri, United States

Site Status

Memorial Sloan Kettering Cancer Center Basking Ridge

Basking Ridge, New Jersey, United States

Site Status

Astera Cancer Care East Brunswick

East Brunswick, New Jersey, United States

Site Status

Memorial Sloan Kettering Cancer Center at Bergen

Montvale, New Jersey, United States

Site Status

San Juan Oncology Associates

Farmington, New Mexico, United States

Site Status

MSKCC @ Commack

Commack, New York, United States

Site Status

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Site Status

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Providence Portland Medical Ctr

Portland, Oregon, United States

Site Status

Roper St. Francis Healthcare

Charleston, South Carolina, United States

Site Status

West Cancer Center

Germantown, Tennessee, United States

Site Status

Sarah Cannon Research Institute / Tennessee Oncology

Nashville, Tennessee, United States

Site Status

Texas Oncology - DFW

Dallas, Texas, United States

Site Status

The Center for Cancer and Blood Disorders - Fort Worth

Fort Worth, Texas, United States

Site Status

Baylor St. Luke's Medical Center

Houston, Texas, United States

Site Status

Houston Methodist Hospital

Houston, Texas, United States

Site Status

Inova Fairfax Hospital

Fairfax, Virginia, United States

Site Status

Virginia Oncology Associates

Norfolk, Virginia, United States

Site Status

Northwest Medical Specialties

Tacoma, Washington, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

Centro de Investigaciones Médicas y Desarrollo LC S.R.L

Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

Site Status

Hospital de Onc Angel Roffo

Buenos Aires, , Argentina

Site Status

Organización medica de Investi

Cap Fed, , Argentina

Site Status

Hospital Britanico

Ciudad Autonoma Bs As, , Argentina

Site Status

Hospital Provincial del Centenario

Rosario, , Argentina

Site Status

Instituto de Oncología de Rosario

Rosario, , Argentina

Site Status

CEMER Centro Medico de Enfermedades Respiratorias

Vicente López, , Argentina

Site Status

Calvary Mater Newcastle

Waratah, New South Wales, Australia

Site Status

Mater Hospital Brisbane

South Brisbane, Queensland, Australia

Site Status

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Site Status

Peter MacCallum Cancer Centre-East Melbourne

Melbourne, Victoria, Australia

Site Status

Sunshine Hospital

St Albans, Victoria, Australia

Site Status

Fiona Stanley Hospital - Medical Oncology

Murdoch, Western Australia, Australia

Site Status

Uniklinikum Salzburg, LKH

Salzburg, , Austria

Site Status

A.Ö. LHK

Steyr, , Austria

Site Status

Medizinische Universität Wien

Vienna, , Austria

Site Status

Cliniques Universitaires St-Luc

Brussels, , Belgium

Site Status

Jessa Zkh (Campus Virga Jesse)

Hasselt, , Belgium

Site Status

Hospital Sao Rafael - HSR

Salvador, Estado de Bahia, Brazil

Site Status

Hospital Araujo Jorge

Goiânia, Goiás, Brazil

Site Status

Hospital do Cancer de Pernambuco - HCP

Recife, Pernambuco, Brazil

Site Status

Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Sao Lucas - PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital de Base de Sao Jose do Rio Preto

São José do Rio Preto, São Paulo, Brazil

Site Status

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

São Paulo, São Paulo, Brazil

Site Status

Beneficencia Portuguesa de Sao Paulo

São Paulo, São Paulo, Brazil

Site Status

Arthur J.E. Child Comprehensive Cancer Center-Calgary

Calgary, Alberta, Canada

Site Status

BC Cancer ? Surrey

Surrey, British Columbia, Canada

Site Status

Royal Victoria Regional Health Centre

Barrie, Ontario, Canada

Site Status

William Osler Health System Brampton Civic Hospital

Brampton, Ontario, Canada

Site Status

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

Site Status

Princess Margaret Cancer Center

Toronto, Ontario, Canada

Site Status

Universite de Montreal - Hopital Maisonneuve-Rosemont

Montreal, Quebec, Canada

Site Status

Centre Hospitalier de l?Université de Montréal (CHUM)

Montreal, Quebec, Canada

Site Status

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

McGill University Health Center

Montreal, Quebec, Canada

Site Status

Hopital du Saint Sacrement

Québec, Quebec, Canada

Site Status

Anyang Tumor Hosptial

Anyang, , China

Site Status

Affiliated Hospital of Hebei University

Baoding, , China

Site Status

Beijing Cancer Hospital

Beijing, , China

Site Status

the First Affiliated Hospital of Bengbu Medical College

Bengbu, , China

Site Status

The First Hospital of Jilin University

Changchun, , China

Site Status

Hunan Cancer Hospital

Changsha, , China

Site Status

Fujian Medical University Union Hospital

Fujian, , China

Site Status

Sun Yat-sen Memorial Hospital

Guangzhou, , China

Site Status

Sun Yet-sen University Cancer Center

Guangzhou, , China

Site Status

Sir Run Run Shaw Hospital Zhejiang University

Hangzhou, , China

Site Status

Zhejiang Cancer Hospital

Hangzhou, , China

Site Status

Harbin Medical University Cancer Hospital

Harbin, , China

Site Status

Shandong Cancer Hospital

Jinan, , China

Site Status

Guangxi Cancer Hospital of Guangxi Medical University

Nanning, , China

Site Status

Shengjing Hospital of China Medical University

Shenyang, , China

Site Status

Liaoning cancer Hospital & Institute

Shenyang, , China

Site Status

The First Affiliated Hospital of Xian Jiao Tong University

Xi'an, , China

Site Status

Herlev Hospital

Herlev, , Denmark

Site Status

Sjællands Universitetshospital, Næstved

Næstved, , Denmark

Site Status

Odense Universitetshospital, Onkologisk Afdeling R

Odense C, , Denmark

Site Status

ICO Paul Papin

Angers, , France

Site Status

Centre Hospitalier de La Cote Basque

Bayonne, , France

Site Status

Chd de Vendee

La Roche-sur-Yon, , France

Site Status

Institut régional du Cancer Montpellier

Montpellier, , France

Site Status

Chu La Miletrie

Poitiers, , France

Site Status

Institut Jean Godinot

Reims, , France

Site Status

Centre Eugene Marquis

Rennes, , France

Site Status

ICL

Saint-Priest-en-Jarez, , France

Site Status

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, , France

Site Status

Ambulantes Tumorzentrum Spandau

Berlin, , Germany

Site Status

Klinikum Chemnitz gGmbH

Chemnitz, , Germany

Site Status

Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden

Dresden, , Germany

Site Status

Universitätsklinikum Essen

Essen, , Germany

Site Status

Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH

Georgsmarienhütte, , Germany

Site Status

Dres.Andreas Ammon und Dirk Meyer

Göttingen, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Facharztzentrum Eppendorf, Studien GbR

Hamburg, , Germany

Site Status

Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie

Hanover, , Germany

Site Status

Nationales Centrum für Tumorerkrankungen (NCT)

Heidelberg, , Germany

Site Status

Praxis Köppler, Heymann, Weide, Thomalla

Koblenz, , Germany

Site Status

Dres. Andreas Köhler und Roswitha Fuchs

Langen, , Germany

Site Status

St. Elisabeth-Krankenhaus, Senologie/Brustzentrum

Leipzig, , Germany

Site Status

Universitätsklinikum Mannheim

Mannheim, , Germany

Site Status

Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt

München, , Germany

Site Status

MVZ für Hämatologie und Onkologie Ravensburg GmBH

Ravensburg, , Germany

Site Status

Klinikum Mutterhaus der Borromaeerinnen gGmbH

Trier, , Germany

Site Status

Dres. Helmut Forstbauer, Carsten Ziske und Kollegen

Troisdorf, , Germany

Site Status

Universitätsklinik Tübingen

Tübingen, , Germany

Site Status

Anticancer Hospital Ag Savas

Athens, , Greece

Site Status

Anticancer Hospital Ag. Savas

Athens, , Greece

Site Status

Euromedical General Clinic of Thessaloniki

Thessaloniki, , Greece

Site Status

European Interbalkan Medical Center

Thessaloniki, , Greece

Site Status

Pamela Youde Nethersole Eastern Hospital

Hong Kong, , Hong Kong

Site Status

Princess Margaret Hospital

Hong Kong, , Hong Kong

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

Honvédelmi Minisztérium Állami Egészségügyi Központ;Onkológiai Osztály

Budapest, , Hungary

Site Status

Budapesti Uzsoki Utcai Kórház

Budapest, , Hungary

Site Status

Davidof Center - Rabin Medical Center

Petah Tikva, , Israel

Site Status

Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Tel Aviv Sourasky Medical Ctr

Tel Aviv, , Israel

Site Status

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola

Meldola, Emilia-Romagna, Italy

Site Status

IRCCS Istituto Regina Elena (IFO)

Rome, Lazio, Italy

Site Status

Az. Osp. Spedali Civili

Brescia, Lombardy, Italy

Site Status

Istituto Europeo Di Oncologia

Milan, Lombardy, Italy

Site Status

Asst Di Monza

Monza, Lombardy, Italy

Site Status

Humanitas Centro Catanese Di Oncologia

Misterbianco (CT), Sicily, Italy

Site Status

Fondazione del Piemonte per l?Oncologia (IRCCS)

Candiolo, Trentino-Alto Adige, Italy

Site Status

Ospedale Civile - Livorno

Livorno, Tuscany, Italy

Site Status

Ospedale Sacro Cuore Don Calabria

Negrar, Veneto, Italy

Site Status

IOV - Istituto Oncologico Veneto - IRCCS

Padua, Veneto, Italy

Site Status

Azienda ULSS 8 Berica

Vicenza, Veneto, Italy

Site Status

Nagoya University Hospital

Aichi, , Japan

Site Status

Chiba Cancer Center

Chiba, , Japan

Site Status

National Cancer Center Hospital East

Chiba, , Japan

Site Status

National Hospital Organization Kyushu Cancer Center

Fukuoka, , Japan

Site Status

Hiroshima City Hiroshima Citizens Hospital

Hiroshima, , Japan

Site Status

Hiroshima University Hospital

Hiroshima, , Japan

Site Status

National Hospital Organization Hokkaido Cancer Center

Hokkaido, , Japan

Site Status

Hyogo Cancer Center

Hyōgo, , Japan

Site Status

University of Tsukuba Hospital

Ibaraki, , Japan

Site Status

Sagara Hospital

Kagoshima, , Japan

Site Status

Kanagawa Cancer Center

Kanagawa, , Japan

Site Status

Tokai University Hospital

Kanagawa, , Japan

Site Status

Kumamoto University Hospital

Kumamoto, , Japan

Site Status

Fukushima Medical University Hospital

Miyagi, , Japan

Site Status

Niigata Cancer Center Hospital

Niigata, , Japan

Site Status

Naha-nishi Clinic

Okinawa, , Japan

Site Status

National Hospital Organization Osaka National Hospital

Osaka, , Japan

Site Status

Osaka International Cancer Institute

Osaka, , Japan

Site Status

Saitama Cancer Center

Saitama, , Japan

Site Status

National Cancer Center Hospital

Tokyo, , Japan

Site Status

The Cancer Institute Hospital of JFCR

Tokyo, , Japan

Site Status

Showa Medical University Hospital

Tokyo, , Japan

Site Status

Health Pharma Professional Research

CD Mexico, Mexico CITY (federal District), Mexico

Site Status

Centro de Atencion Oncologica Viva S de RL de CV

Mexico City, Mexico CITY (federal District), Mexico

Site Status

Filios Alta Medicina

Monterrey, Nuevo León, Mexico

Site Status

Centro de Investigacion Clinica de Oaxaca

Oaxaca City, Oaxaca, Mexico

Site Status

Oncologico Potosino

San Luis Potosí City, San Luis Potosí, Mexico

Site Status

Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde

Morelia, , Mexico

Site Status

Sociedad de Metabolismo y Corazón (SOMECO)

Veracruz, , Mexico

Site Status

Auckland City Hospital

Auckland, , New Zealand

Site Status

Oncosalud Sac

Lima, , Peru

Site Status

Instituto Peruano de Oncología y Radioterapia

Lima, , Peru

Site Status

Instituto Nacional de Enfermedades Neoplasicas

Lima, , Peru

Site Status

Instituto Regional de Enfermedades Neoplasicas - IREN Norte

Trujillo, , Peru

Site Status

Uniwersyteckie Centrum Kliniczne

Gda?sk, , Poland

Site Status

Szpital Morski im. PCK

Gdynia, , Poland

Site Status

Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad

Warsaw, , Poland

Site Status

IPO de Coimbra

Coimbra, , Portugal

Site Status

Hospital da Luz

Lisbon, , Portugal

Site Status

Centro Hospitalar Lisboa Norte

Lisbon, , Portugal

Site Status

IPO do Porto

Porto, , Portugal

Site Status

SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"

Moskva, Moscow Oblast, Russia

Site Status

Podolsk City Clinical Hospital

Podolsk, Moscow Oblast, Russia

Site Status

Respublikanskiy Onkologicheskiy Dispanser

Saransk, Respublika Mordoviya, Russia

Site Status

Ryazan Regional clinical oncology dispensary

Ryazan, Ryazan Oblast, Russia

Site Status

GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)

Saint Petersburg, Sankt-Peterburg, Russia

Site Status

Chelyabinsk region oncology dispensary

Chelyabinsk, , Russia

Site Status

Multidisciplinary clinic Reaviz

Samara, , Russia

Site Status

Chungbuk National University Hospital

Cheongju-si, , South Korea

Site Status

Kyungpook National University Medical Center

Daegu, , South Korea

Site Status

National Cancer Center

Gyeonggi-do, , South Korea

Site Status

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Korea University Anam Hospital

Seoul, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Gangnam Severance Hospital

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Korea University Guro Hospital

Seoul, , South Korea

Site Status

Ulsan University Hosiptal

Ulsan, , South Korea

Site Status

Hospital Duran i Reynals

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Corporacio Sanitaria Parc Tauli

Sabadell, Barcelona, Spain

Site Status

Hospital de Donostia

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Hospital Quiron de Madrid

Pozuelo de Alarcón, Madrid, Spain

Site Status

Complejo Hospitalario Universitario A Coruña (CHUAC)

A Coruña, , Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hospital Universitari Dexeus - Grupo Quironsalud

Barcelona, , Spain

Site Status

Vall d?Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, , Spain

Site Status

Hospital General Universitario Gregorio Marañon

Madrid, , Spain

Site Status

Centro Oncologico MD Anderson Internacional

Madrid, , Spain

Site Status

Hospital Ramon y Cajal

Madrid, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

HM Sanchinarro ? CIOCC

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocio

Seville, , Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung Uni Hospital

Tainan, , Taiwan

Site Status

Veterans General Hospital

Taipei, , Taiwan

Site Status

National Taiwan Uni Hospital

Taipei, , Taiwan

Site Status

Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hosipital at Linkou

Taoyuan Hsien, , Taiwan

Site Status

Chulalongkorn Hospital, Faculty of Medicine

Bangkok, , Thailand

Site Status

Rajavithi Hospital

Bangkok, , Thailand

Site Status

Ramathibodi Hospital

Bangkok, , Thailand

Site Status

Maharaj Nakorn Chiang Mai Hosp

Chang Mai, , Thailand

Site Status

Songklanagarind Hospital

Songkhla, , Thailand

Site Status

Hacettepe Uni Medical Faculty Hospital

Ankara, , Turkey (Türkiye)

Site Status

Ankara Bilkent City Hospital

Ankara, , Turkey (Türkiye)

Site Status

Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

Edirne, , Turkey (Türkiye)

Site Status

Medipol University Medical Faculty

Istanbul, , Turkey (Türkiye)

Site Status

Katip Celebi University Ataturk Training and Research Hospital

Izmir, , Turkey (Türkiye)

Site Status

Kocaeli University Faculty of Medicine

İzmit, , Turkey (Türkiye)

Site Status

Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department

Malatya, , Turkey (Türkiye)

Site Status

19 Mayis University Medical Faculty

Samsun, , Turkey (Türkiye)

Site Status

Municipal Institution City Clinical Hospital #4 of Dnipro City Council

Dnipropetrovsk, Katerynoslav Governorate, Ukraine

Site Status

SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU

Kharkiv, Kharkiv Governorate, Ukraine

Site Status

Ivano-Frankivsk Regional Oncology Center

Ivano-Frankivsk, , Ukraine

Site Status

ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council

Kryvyi Rih, , Ukraine

Site Status

Sumy Regional Clinical Onc Ctr

Sumy, , Ukraine

Site Status

Royal Sussex County Hospital

Brighton, , United Kingdom

Site Status

Leicester Royal Infirmary

Leicester, , United Kingdom

Site Status

University College London Hospital

London, , United Kingdom

Site Status

Royal Free Hospital

London, , United Kingdom

Site Status

Guys & St Thomas Hospital

London, , United Kingdom

Site Status

Maidstone Hospital

Maidstone, , United Kingdom

Site Status

Peterborough City Hospital

Peterborough, , United Kingdom

Site Status

Derriford Hospital

Plymouth, , United Kingdom

Site Status

Royal Marsden Hosp NHS Fnd

Sutton, , United Kingdom

Site Status

Royal Cornwall Hospital

Truro, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada China Denmark France Germany Greece Hong Kong Hungary Israel Italy Japan Mexico New Zealand Peru Poland Portugal Russia South Korea Spain Taiwan Thailand Turkey (Türkiye) Ukraine United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-000119-66

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2023-506911-16-00

Identifier Type: CTIS

Identifier Source: secondary_id

BO41843

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.